Latest Derivatives News

Perpetual Resources has reported outstanding high-grade tin, tantalum, titanium, and niobium mineralisation from reconnaissance sampling at its Itinga Project in Brazil, revealing significant exploration upside in a historically underexplored region.

Citigroup Global Markets Australia has announced a partially franked dividend of AUD 0.12 for the IAG CitiFirst Self-Funding Instalments, aligning key dates with IAG ordinary shares and reducing the outstanding loan balance.

Citigroup Global Markets Australia has announced a fully franked AUD 0.30 dividend for its ORG CitiFirst Instalments, with key dates set for early March 2025.

Citigroup Global Markets Australia has announced a fully franked dividend of AUD 0.30 for its ORG CitiFirst Instalment MINIs, aligning key dates with the ORG Ordinary shares. Investors should note the ex-dividend date on 4 March 2025 and the dividend payment expected on 28 March 2025.

Australian Mines Limited reports robust assay results from its auger drilling campaign at the Jequie Rare Earth Element Project in Brazil, highlighting significant TREO concentrations and promising targets for further exploration.

GQG Partners reported a stellar 2024 with net inflows doubling to US$20.2 billion and funds under management climbing nearly 27%, underpinning strong revenue and earnings growth. The firm also expanded its dividend payout range, signaling confidence in future capital management.

Ragnar Metals has identified multiple large conductive anomalies at its Viken Project in Sweden, reinforcing the potential for significant uranium, vanadium, and molybdenum mineralisation. These findings, derived from reprocessed VLF geophysics and historical drilling data, set the stage for targeted exploration.

Citigroup Global Markets Australia confirms a fully franked AUD 2.25 dividend for CBA CitiFirst Instalment MINIs, aligning key dates with CBA ordinary shares.

Neurotech International has inked a development deal with RH Farma to produce a pharmaceutical-grade cannabinoid drug targeting pediatric neurodevelopmental disorders, leveraging advanced European extraction technology.

ASX Limited delivered a robust first half in 2025 with record operating revenue and a 10% rise in underlying NPAT, underscoring its strategic focus on technology modernisation and disciplined cost management.

ASX Limited has reported a robust first half of FY25 with record operating revenue and a near 10% rise in underlying net profit, underpinned by strong growth across key business segments and a strategic focus on technology modernization.

Insurance Australia Group Limited has announced a quarterly distribution of AUD 1.5191 per Capital Note 3 security, partially franked at 60%, payable on March 17, 2025.